Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Hypertens Res ; 41(9): 699-707, 2018 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-29950683

RESUMEN

The ATP2B1 gene is associated with hypertension. We previously reported that systemic heterozygous ATP2B1-null (ATP2B1+/-) mice exhibited hypertension due to impaired endothelial nitric oxide synthase (eNOS) activity and decreased nitric oxide (NO) production. The ATP2B1 gene encodes plasma membrane calcium ATPase 1 (PMCA1), which has been thought to regulate only intracellular Ca2+ concentration. However, recently, it has been suggested that ATP2B1 works not only at cellular levels, but also throughout the entire body, including in the calcium metabolism, using small intestine-specific ATP2B1 knockout mice. To clarify the roles of ATP2B1 in the entire body and the effects of ATP2B1 on blood pressure, we examined the alterations of calcium related factors in ATP2B1+/- mice. ATP2B1+/- mice exhibited hypocalcemia. The expression of ATP2B1 in the kidney and small intestine decreased, and hypercalciuria was confirmed in ATP2B1+/- mice. The intact-PTH levels were lower, and bone mineral density was increased in these mice. These results suggest that hypocalcemia is mainly a result of inhibited bone resorption without compensation by PTH secretion in the case of ATP2B1 knockout. Moreover, NO production may be affected by reduced PTH secretion, which may cause the increase in vascular contractility in these mice. The ATP2B1 gene is important for not only intra-cellular calcium regulation but also for calcium homeostasis and blood pressure control.


Asunto(s)
Hipertensión/metabolismo , Hipocalcemia/metabolismo , Hormona Paratiroidea/sangre , ATPasas Transportadoras de Calcio de la Membrana Plasmática/genética , Animales , Densidad Ósea , Calcio/metabolismo , Masculino , Ratones , Óxido Nítrico/biosíntesis , Fósforo/sangre , ATPasas Transportadoras de Calcio de la Membrana Plasmática/fisiología
2.
Atherosclerosis ; 240(1): 297-304, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25818388

RESUMEN

OBJECTIVE: There is no clinical evidence that supports the benefit of integrative medicine, defined as combination therapy of oriental and western medicine, on obesity-related hypertension. This study evaluates the efficacy of Bofu-tsusho-san (BOF), an oriental herbal medicine, on the ambulatory blood pressure (BP) profile in hypertensive patients with obesity. METHODS: The study design was a multicenter, randomized, open-label, parallel-group controlled trial in 107 hypertensive patients with obesity. Participants were randomly assigned to receive either the conventional control therapy or BOF add-on therapy. In both groups antihypertensive therapy was aimed at achieving the target clinic BP. The primary outcome was change in the ambulatory BP profile from baseline to 24 weeks after randomization. RESULTS: Daytime systolic BP variability, an important parameter of ambulatory BP profile, was decreased in the BOF group, and the difference in the changes in daytime systolic BP variability was significant between the BOF and control group (Control vs BOF; the change from baseline in daytime systolic BP variability, 1.0±3.3 vs -1.0±3.3%; p=0.006). CONCLUSION: The BOF add-on therapy effectively improved the ambulatory BP variability. This is the first report suggesting that an integrative medicine approach may exert favorable effects on obesity-related hypertension compared with conventional pharmaceutical treatment. CLINICAL TRIAL REGISTRATION: UMIN000003878.


Asunto(s)
Antihipertensivos/uso terapéutico , Presión Sanguínea/efectos de los fármacos , Medicamentos Herbarios Chinos/uso terapéutico , Hipertensión/tratamiento farmacológico , Obesidad/complicaciones , Anciano , Antihipertensivos/efectos adversos , Monitoreo Ambulatorio de la Presión Arterial , Quimioterapia Combinada , Medicamentos Herbarios Chinos/efectos adversos , Femenino , Humanos , Hipertensión/diagnóstico , Hipertensión/etiología , Hipertensión/fisiopatología , Japón , Masculino , Persona de Mediana Edad , Fitoterapia , Plantas Medicinales , Estudios Prospectivos , Factores de Tiempo , Resultado del Tratamiento
3.
Ther Apher Dial ; 19(2): 131-7, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25257861

RESUMEN

This study aimed to evaluate the effect of different timings of iron administration during erythropoiesis activated by continuous erythropoietin receptor activator (CERA) on reticulocyte iron uptake in hemodialysis patients. In total, 110 patients were randomized to receive 40 mg intravenous elemental iron doses at all three hemodialysis sessions in the first week (IW1 group: n = 57) or in the third week (IW3 group: n = 53) after CERA administration. Following CERA administration at day 0, reticulocyte count increased, peaking at day 7. At days 7 and 14, the observed changes in Ret-He were higher in the IW1 group than in the IW3 group. Increases in total reticulocyte hemoglobin at day 7 were higher in the IW1 group than in the IW3 group. In contrast, there was only tendency toward greater total reticulocyte hemoglobin after iron administration in the third week in the IW3 group. Intravenous iron supplementation in the first week of CERA administration increases reticulocyte iron uptake; however, iron supplementation in the third week does not. The findings indicate that iron should be intravenously administered to increase the efficacy of CERA within 1 week of CERA administration during highly active erythropoiesis.


Asunto(s)
Eritropoyesis/efectos de los fármacos , Eritropoyetina/uso terapéutico , Hierro/metabolismo , Hierro/uso terapéutico , Fallo Renal Crónico/terapia , Polietilenglicoles/uso terapéutico , Diálisis Renal , Administración Intravenosa , Anciano , Eritropoyetina/administración & dosificación , Femenino , Estudios de Seguimiento , Pruebas Hematológicas , Humanos , Hierro/administración & dosificación , Fallo Renal Crónico/metabolismo , Masculino , Polietilenglicoles/administración & dosificación , Reticulocitos/efectos de los fármacos , Reticulocitos/metabolismo
5.
PLoS One ; 8(10): e75560, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24130717

RESUMEN

Accumulating evidence indicates that metabolic dysfunction with visceral obesity is a major medical problem associated with the development of hypertension, type 2 diabetes (T2DM) and dyslipidemia, and ultimately severe cardiovascular and renal disease. Therefore, an effective anti-obesity treatment with a concomitant improvement in metabolic profile is important for the treatment of metabolic dysfunction with visceral obesity. Bofu-tsu-shosan (BOF) is one of oriental herbal medicine and is clinically available to treat obesity in Japan. Although BOF is a candidate as a novel therapeutic strategy to improve metabolic dysfunction with obesity, the mechanism of its beneficial effect is not fully elucidated. Here, we investigated mechanism of therapeutic effects of BOF on KKAy mice, a model of human metabolic disorders with obesity. Chronic treatment of KKAy mice with BOF persistently decreased food intake, body weight gain, low-density lipoprotein cholesterol and systolic blood pressure. In addition, both tissue weight and cell size of white adipose tissue (WAT) were decreased, with concomitant increases in the expression of adiponectin and peroxisome proliferator-activated receptors genes in WAT as well as the circulating adiponectin level by BOF treatment. Furthermore, gene expression of uncoupling protein-1, a thermogenesis factor, in brown adipose tissue and rectal temperature were both elevated by BOF. Intriguingly, plasma acylated-ghrelin, an active form of orexigenic hormone, and short-term food intake were significantly decreased by single bolus administration of BOF. These results indicate that BOF exerts a combinatorial favorable metabolic modulation including antihypertensive effect, at least partially, via its beneficial effect on adipose tissue function and its appetite-inhibitory property through suppression on the ghrelin system.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Medicina de Hierbas/métodos , Enfermedades Metabólicas/tratamiento farmacológico , Obesidad Abdominal/tratamiento farmacológico , Animales , Presión Sanguínea/efectos de los fármacos , Modelos Animales de Enfermedad , Humanos , Canales Iónicos/metabolismo , Enfermedades Metabólicas/metabolismo , Ratones , Proteínas Mitocondriales/metabolismo , Obesidad Abdominal/metabolismo , Proteína Desacopladora 1
6.
Hypertens Res ; 29(3): 143-51, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16755149

RESUMEN

The importance of tight blood pressure (BP) control has been established. We performed cross-sectional studies on the current status of BP control and the prescription and efficacy of antihypertensive drugs in hypertensive patients in Japan. The data were also evaluated in subgroups with or without diabetes mellitus (DM) and in winter and summer. Analyses were performed on the collected data of 12,437 treated hypertensive patients in winter and 5,972 in summer 2002. In winter, 50.3% of patients received calcium channel blockers (CCBs), 15.3% received angiotensin converting enzyme inhibitors (ACEIs) and 11.0% received angiotensin receptor blockers (ARBs). In the patients receiving monotherapy, 69% of patients received a CCB, 13% an ACEI and 11.0% an ARB. A total of 2,918 patients received combination therapy, and CCBs were the most frequently (89.6%) prescribed component of such therapy. Prescriptions of beta-blockers (BBs) decreased and those of CCBs and diuretics (D) increased with age (p<0.001). The rate of patients with adequately controlled BP less than 140/90 mmHg was 40.3% in the CCB group, 37.6% in the D group, and 36.9% in the BB group (p<0.001). In patients receiving combination therapy, those with CCB+D had the best rate of BP control (40.7%). The rate of patients with adequately controlled BP was lower in winter than in summer at both a target BP of 140/90 mmHg (36.2% vs. 43.8%, p<0.001) and a target BP of 130/85 mmHg in patients younger than 60 years old (15.5% vs. 18.6%, p<0.02). In diabetic patients, the target BP (130/80 mmHg) was achieved in only 11.3%, which was lower (p<0.05) than the rate in non-diabetic patients (13.1%). In conclusion, the present cross-sectional study showed that CCBs were the most frequently prescribed agent for the treatment of hypertension in Japan. The rate of adequate BP control was less than 50% and was even worse in patients with DM and in winter. Our results indicate that physicians should treat hypertension more intensively to achieve the target BP.


Asunto(s)
Antihipertensivos/uso terapéutico , Hipertensión/tratamiento farmacológico , Antagonistas Adrenérgicos beta/uso terapéutico , Anciano , Anciano de 80 o más Años , Bloqueadores del Receptor Tipo 1 de Angiotensina II/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Presión Sanguínea/fisiología , Ejercicios Respiratorios , Bloqueadores de los Canales de Calcio/uso terapéutico , Estudios Transversales , Diabetes Mellitus/fisiopatología , Diuréticos/uso terapéutico , Combinación de Medicamentos , Femenino , Humanos , Hipertensión/fisiopatología , Japón , Masculino , Persona de Mediana Edad , Estaciones del Año
7.
Biochem Biophys Res Commun ; 334(3): 861-6, 2005 Sep 02.
Artículo en Inglés | MEDLINE | ID: mdl-16036219

RESUMEN

Sarcolipin, a homologue of phospholamban, regulates Ca2+ uptake through the interaction with sarcoplasmic reticulum Ca2+ ATPase (SERCA) and is predominantly expressed in the atrial muscle. Although the atrial chamber-specific expression of sarcolipin could be primarily regulated at the transcriptional level, the transcriptional regulation remains poorly understood. Since mechanical stress plays an important role in transcriptional regulation of a gene involved in cardiac hypertrophy and remodeling, we generated left-sided or right-sided pressure-overload models by transverse aortic constriction (TAC) in ddY mice or by monocrotaline administration in Wistar rats, respectively. TAC significantly decreased the expression of sarcolipin, SERCA2a, and phospholamban mRNAs in the left atrium (LA) than those in the right atrium (RA). By contrast, monocrotaline administration significantly decreased the expression of sarcolipin, SERCA2a, and phospholamban mRNAs in the RA than those in the LA. The two independent complementary experiments unequivocally demonstrated that mechanical stress down-regulates the transcription of the sarcolipin gene.


Asunto(s)
Atrios Cardíacos/metabolismo , Proteínas Musculares/genética , Proteolípidos/genética , Estrés Mecánico , Animales , Aorta/patología , Proteínas de Unión al Calcio/biosíntesis , ATPasas Transportadoras de Calcio/biosíntesis , Cardiomegalia/fisiopatología , Constricción Patológica , Regulación hacia Abajo , Regulación de la Expresión Génica , Masculino , Ratones , Monocrotalina/toxicidad , Tamaño de los Órganos , Ratas , Ratas Wistar , ATPasas Transportadoras de Calcio del Retículo Sarcoplásmico
8.
J Biol Chem ; 279(25): 26274-9, 2004 Jun 18.
Artículo en Inglés | MEDLINE | ID: mdl-15087458

RESUMEN

APJ is a G-protein-coupled receptor with seven transmembrane domains, and its endogenous ligand, apelin, was identified recently. They are highly expressed in the cardiovascular system, suggesting that APJ is important in the regulation of blood pressure. To investigate the physiological functions of APJ, we have generated mice lacking the gene encoding APJ. The base-line blood pressure of APJ-deficient mice is equivalent to that of wild-type mice in the steady state. The administration of apelin transiently decreased the blood pressure of wild-type mice and a hypertensive model animal, a spontaneously hypertensive rat. On the other hand, this hypotensive response to apelin was abolished in APJ-deficient mice. This apelin-induced response was inhibited by pretreatment with a nitric-oxide synthase inhibitor, and apelin-induced phosphorylation of endothelial nitric-oxide synthase in lung endothelial cells from APJ-deficient mice disappeared. In addition, APJ-deficient mice showed an increased vasopressor response to the most potent vasoconstrictor angiotensin II, and the base-line blood pressure of double mutant mice homozygous for both APJ and angiotensin-type 1a receptor was significantly elevated compared with that of angiotensin-type 1a receptor-deficient mice. These results demonstrate that APJ exerts the hypotensive effect in vivo and plays a counterregulatory role against the pressor action of angiotensin II.


Asunto(s)
Receptor de Angiotensina Tipo 1/química , Receptores Acoplados a Proteínas G/fisiología , Alelos , Angiotensina II/metabolismo , Animales , Receptores de Apelina , Presión Sanguínea , Northern Blotting , ADN Complementario/metabolismo , Endotelio/enzimología , Endotelio Vascular/metabolismo , Inhibidores Enzimáticos/farmacología , Homocigoto , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Mutantes , Modelos Genéticos , NG-Nitroarginina Metil Éster/metabolismo , Óxido Nítrico Sintasa/antagonistas & inhibidores , Fosforilación , Estructura Terciaria de Proteína , ARN/metabolismo , Ratas , Ratas Endogámicas WKY , Receptor de Angiotensina Tipo 1/metabolismo , Receptores Acoplados a Proteínas G/metabolismo , Recombinación Genética , Serina/química , Factores de Tiempo
9.
Intern Med ; 41(11): 957-60, 2002 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12487167

RESUMEN

A 47-year-old Japanese woman with a continuing high fever was promptly diagnosed as having infected atrial myxoma one day after admission based on transthoracic echocardiographic findings and positivity for bacteria in blood culture. The mass was removed by an urgent open heart surgery. Histopathological examination confirmed that this mass was a myxoma with gram-positive bacterial colonies. Generally, antemortem diagnosis is difficult and there is a high mortality of patients with infected myxoma; however, this patient completely recovered from the illness because of the prompt diagnosis. This is the 37th case of definite infected myxoma reported in the literature. The cause of infection of this patient might have been the acupuncture therapy she underwent for weight reduction.


Asunto(s)
Cardiomiopatías/complicaciones , Neoplasias Cardíacas/complicaciones , Mixoma/complicaciones , Infecciones Estreptocócicas/complicaciones , Streptococcus bovis , Femenino , Atrios Cardíacos , Humanos , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA